The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BRCA1-like copy number profiles to predict benefit of high-dose alkylating chemotherapy in high-risk breast cancer (BC): Results from randomized WSG AM-01 trial.
Philip C. Schouten
No relevant relationships to disclose
Oleg Gluz
No relevant relationships to disclose
Nadia Harbeck
No relevant relationships to disclose
Svjetlana Mohrmann
No relevant relationships to disclose
Raihana Diallo-Danebrock
No relevant relationships to disclose
Enrico Pelz
No relevant relationships to disclose
Janneke Kruizinga
No relevant relationships to disclose
Arno Velds
No relevant relationships to disclose
Marja Nieuwland
No relevant relationships to disclose
Ron M. Kerkhoven
No relevant relationships to disclose
Cornelia Liedtke
No relevant relationships to disclose
Markus Frick
No relevant relationships to disclose
Ronald Kates
No relevant relationships to disclose
Sabine C. Linn
No relevant relationships to disclose
Ulrike Nitz
No relevant relationships to disclose
Frederik Marme
No relevant relationships to disclose